Global /China /Healthcare /Drug Manufacturers - General /688553

Sichuan Huiyu Pharmaceutical Co., Ltd.

688553

• SSE: 688553 • Delayed

19.98CNY 2.4%

2.95 USD

As of 16 June 2026, Sichuan Huiyu Pharmaceutical Co., Ltd. has a market cap of $1.21B USD, ranking #9622 globally and #2619 in China. It ranks #836 in the Healthcare sector, and #317 in the Drug Manufacturers - General industry.

Global Rank

9622

Country Rank

2619

Sector Rank

836

Industry Rank

317

Key Stats

Market Cap

$1.21BUSD

8.22B CNY

Enterprise Value

$907.26MUSD

6.14B CNY

Revenue (TTM)

$151.86MUSD

1.03B CNY

EBITDA (TTM)

$23.97MUSD

162.22M CNY

Net Income (TTM)

$3.33MUSD

22.53M CNY

EBITDA Margin

16%

Profit Margin

2.2%

PE Ratio

364.9

PS Ratio

8.0

PB Ratio

2.2

EV/EBITDA

37.5

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Zhao Ding open_in_new

Employees

1,331

Founded

2010

Website

huiyupharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.4%	3.6%	15%	3.8%	-3.1%	12%	41%	20%	-60%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688553 四川汇宇制药股份有限公司 Class A ISIN: CNE100004ZT4 Shares Out.: Shares Outstanding: 423.6M¹ Shares Float: 276.49M² TV: TradingView: SSE: 688553 SA: Stock Analysis: SHA: 688553 YF: Yahoo Finance: 688553.SS GF: Google Finance: SHA: 688553 BA: Barron's: 688553 MS: Morningstar: XSHG: 688553	19.98 CNY	TV: TradingView: SSE: 688553 SA: Stock Analysis: SHA: 688553 YF: Yahoo Finance: 688553.SS GF: Google Finance: SHA: 688553 BA: Barron's: 688553 MS: Morningstar: XSHG: 688553

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sichuan Huiyu Pharmaceutical Co., Ltd.

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorportaed in 2010 and is headquartered in Neijiang, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.89B 364.89B CNY 4K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.67B 336.36B CNY 4K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.52B 111.89B CNY 1K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 1K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 63K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 45K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 30K%	97.4	United States
Roche Holding AG SIX: RO	$322.73B 256.25B CHF 26K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.3B 215.59B GBP 24K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$275.68B 218.9B CHF 23K%	20.5	Switzerland

chevron_leftBack